121 related articles for article (PubMed ID: 37062104)
1. Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors.
Zhang C; Yang L; Yang X; Gao Q; Qu Y; Wu L
Bioorg Chem; 2023 Jul; 136():106541. PubMed ID: 37062104
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
3. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
4. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
6. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
7. A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects.
He N; Li L; Li R; Zhang SQ; Wu LH; Guan X; Zhang QY; Jiang T; Yang JB
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240202
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
Wang F; Feng KR; Zhao JY; Zhang JW; Shi XW; Zhou J; Gao D; Lin GQ; Tian P
Bioorg Med Chem; 2020 Dec; 28(24):115822. PubMed ID: 33126089
[TBL] [Abstract][Full Text] [Related]
9. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
10. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
11. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
12. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
Li S; Zhang W; Yang Y; Ma T; Guo J; Wang S; Yu W; Kong L
Eur J Med Chem; 2016 Nov; 124():1006-1018. PubMed ID: 27783972
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
15. Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules.
Zhang W; Ma T; Li S; Yang Y; Guo J; Yu W; Kong L
Eur J Med Chem; 2017 Jan; 125():538-550. PubMed ID: 27718470
[TBL] [Abstract][Full Text] [Related]
16. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
Cai G; Yu W; Song D; Zhang W; Guo J; Zhu J; Ren Y; Kong L
Eur J Med Chem; 2019 Jul; 174():236-251. PubMed ID: 31048139
[TBL] [Abstract][Full Text] [Related]
17. Screening and biological evaluation of a novel STAT3 signaling pathway inhibitor against cancer.
Huang M; Chen Z; Zhang L; Huang Z; Chen Y; Xu J; Zhang J; Shu X
Bioorg Med Chem Lett; 2016 Nov; 26(21):5172-5176. PubMed ID: 27727126
[TBL] [Abstract][Full Text] [Related]
18. 3-Deoxy-2β,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells.
Shan H; Yao S; Ye Y; Yu Q
Acta Pharmacol Sin; 2019 Dec; 40(12):1578-1586. PubMed ID: 31201357
[TBL] [Abstract][Full Text] [Related]
19. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation.
Lu J; Yan X; Lai W; Jiang LH; Shen LQ; Wu AQ; Zhao C
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300526. PubMed ID: 38294206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]